BTIG Reaffirms Celgene (CELG) at 'Buy'; Q3 Results, Update Bolster Confidence
Tweet Send to a Friend
BTIG affirms Celgene Corporation (Nasdaq: CLEG) at Buy with a price target of $138 following Q3 results and update.The firm ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
